New Zealand markets open in 5 hours 48 minutes

OCGN Jan 2025 3.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.17000.0000 (0.00%)
As of 03:42PM EST. Market open.
Full screen
Previous close0.1700
Open0.1500
Bid0.0000
Ask0.3500
Strike3.00
Expiry date2025-01-17
Day's range0.1500 - 0.1900
Contract rangeN/A
Volume4
Open interest811
  • GlobeNewswire

    Ocugen Clinical Showcase Webcast Now Available

    MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website. The showcase replay includes more detail on the Phase 3 study design for OCU400, as well as market potential

  • GlobeNewswire

    Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

    MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the Abu Dhabi Family Office (ADFO) Summit being held February 29—March 1, 2024 at the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab Emirate

  • GlobeNewswire

    Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

    MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximat